Common Contracts
15 similar null contracts by Adicet Bio, Inc., Genenta Science S.p.A., Iris Energy LTD, others
OPAL FUELS INC. Class A Common Stock (par value $0.0001 per share)OPAL Fuels Inc. • November 17th, 2023 • Gas & other services combined • New York
Certain confidential information contained in this document, marked by [***], has been omitted because Iris Energy Limited (the “Company”) has determined that the information (i) is not material and (ii) contains personal information. IRIS ENERGY...Iris Energy LTD • September 13th, 2023 • Finance services • New York
LYRA THERAPEUTICS, INC. Shares of Common Stock (par value $0.001 per share) Controlled Equity OfferingSM Sales AgreementLyra Therapeutics, Inc. • September 1st, 2023 • Surgical & medical instruments & apparatus • New York
Lyra Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co. (the “Agent”), as follows:
Riot Platforms, Inc. Shares of Common Stock (no par value per share) Controlled Equity OfferingSM Sales AgreementRiot Platforms, Inc. • August 9th, 2023 • Finance services • New York
Riot Platforms, Inc., a Nevada corporation (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co., B. Riley Securities, Inc., BTIG, LLC, Roth Capital Partners, LLC, Compass Point Research & Trading, LLC, Northland Securities, Inc., Moelis & Company LLC, and Stifel Nicolaus Canada Inc. (collectively, the “Agents,” and individually, an “Agent”), as follows:
SoundHound AI, Inc. Shares of Common Stock (par value $0.0001 per share) Controlled Equity Offering Sales AgreementSoundhound Ai, Inc. • July 24th, 2023 • Services-prepackaged software • New York
GENENTA SCIENCE S.P.A. American Depositary Shares each representing one ordinary share, no par value per share Controlled Equity OfferingSM Sales AgreementGenenta Science S.p.A. • May 12th, 2023 • Biological products, (no disgnostic substances) • New York
Genenta Science S.p.A., a Republic of Italy joint stock corporation (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co. (the “Agent”), as follows:
Perpetua Resources Corp. Common Shares (without par value) Controlled Equity OfferingSM Sales AgreementPerpetua Resources Corp. • May 12th, 2023 • Gold and silver ores • New York
Perpetua Resources Corp., a corporation incorporated under the Business Corporations Act (British Columbia) (the “BCBCA”) and having its head office located in Boise, Idaho (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co. (the “Agent”), as follows:
KalVista Pharmaceuticals, Inc. Shares of Common Stock (par value $0.001 per share) Controlled Equity OfferingSM Sales AgreementKalVista Pharmaceuticals, Inc. • May 21st, 2021 • Pharmaceutical preparations • New York
KalVista Pharmaceuticals, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co. (the “Agent”), as follows:
Zynerba Pharmaceuticals, Inc. Shares of Common Stock (par value $0.001 per share) Controlled Equity OfferingSM Sales AgreementZynerba Pharmaceuticals, Inc. • May 12th, 2021 • Pharmaceutical preparations • New York
Zynerba Pharmaceuticals, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co., Canaccord Genuity LLC, H.C. Wainwright & Co., LLC and Ladenburg Thalmann & Co. Inc. (each, an “Agent,” and collectively, the “Agents”), as follows:
TherapeuticsMD, Inc. Shares of Common Stock (par value $0.001 per share) Controlled Equity OfferingSM Sales AgreementTherapeuticsMD, Inc. • March 4th, 2021 • Pharmaceutical preparations • New York
TherapeuticsMD, Inc., a Nevada corporation (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co. (the “Agent”), as follows:
Adicet Bio, Inc. Shares of Common Stock (par value $0.0001 per share) Sales AgreementAdicet Bio, Inc. • December 1st, 2020 • Pharmaceutical preparations • New York
Adicet Bio, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Evercore Group L.L.C. and H.C. Wainwright & Co., LLC (each individually an “Agent” and collectively, the “Agents”) as follows:
NOVAVAX, INC. Common Stock (par value $0.01 per share) AT MARKET ISSUANCE SALES AGREEMENTNovavax Inc • November 10th, 2020 • Biological products, (no disgnostic substances) • New York
X4 Pharmaceuticals, Inc. Shares of Common Stock (par value $0.001 per share) Controlled Equity OfferingSM Sales AgreementX4 Pharmaceuticals, Inc • August 7th, 2020 • Biological products, (no disgnostic substances) • New York
PFENEX INC. Common Stock (par value $0.001 per share) Equity Sales AgreementPfenex Inc. • March 15th, 2018 • Pharmaceutical preparations • New York
Pfenex Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with William Blair & Company, L.L.C. (the “Agent”) as follows:
PHYSICIANS REALTY TRUST Common Shares ($0.01 par value per share) At Market Issuance Sales AgreementPhysicians Realty Trust • August 19th, 2014 • Real estate investment trusts • New York
Physicians Realty Trust, a Maryland real estate investment trust (the “Company”), and Physicians Realty L.P., a Delaware limited partnership (the “Operating Partnership”), confirm their agreement (this “Agreement”), with RBC Capital Markets, LLC (“Agent”), as follows:
